The CRISPR patent landscape in 2026 is a complex maze for biotech startups. This article dissects the current state, future implications, and strategic pathways for navigating intellectual property in gene editing.

For US biotech startups in 2026, robust intellectual property protection is paramount to secure innovations, attract investment, and maintain competitive advantage in a rapidly evolving market landscape.